top of page


Small-molecule chemotherapeutics are potent and effective against a variety of malignancies, but common and severe side effects restrict their clinical applications. Nanodrug approaches represent a major focus for improving chemotherapy, but have met limited success. To resolve the bottleneck of chemotherapy drugs, a novel single protein encapsulation (SPE) -based drug formulation and delivery platform is developed. 
Overcome limitation

We have resolve the limitation of the nanodrug through revolutionized technology, and move it from a basic concept into clinical trails.

Pioneer Next Nanodrug

The technology may open up a new avenue for developing new drug delivery systems to improve anticancer therapeutics

Broad Pipeline

Diversed products made from same protein encapsulation technology are completed in preclinical study and moved to clinical trails.

Assemble best team

We have assembled the best team in the science and industry, working smoothly to push this forward

Pioneering Next Generation Nanodrugs for Targeted Treatments of Cancers

Our team has built a robust pipeline of potential first-in-class and/or best-in-class nanodrug for targeted therapeutics. We have an ongoing drug discovery research focus in single protein encapsulation(SPE) – a new generation nanodrug with high potency and low toxicity and low production cost. Our most advanced pipeline programs include SPEDOX, a single protein encapsulated Doxorubicin. The preclinical study has completed and also it is scientifically-validated via publication, potentially much more indications would be applied due to its higher potency, higher dosing and lower toxicity.
Since inception, Sunstate Biosciences’ research focus has been to exploit the concept of single protein encapsulation, an approach for indirectly targeting oncogenic pathways, it does not involve nanoparticle assembly and modifications to either small-molecule drugs or HSA, may open up a new avenue for developing new drug delivery systems to improve anticancer therapeutics.
We have established calibration with  Cedars-Sinai, City of Hope, USC & Caltech to develop the clinical pipelines, SPEDOC, SPEDOXDOC, TRACAM.  We are aggressively pursuing federal government grants, SBIR (NCI & NSF), DOD breast cancer breakthrough awards & NIH R01 academic/industry collaboration research grants. 
Sunstate Biosciences is located in Monrovia, California.
The Company



Founder and CEO/President


Board Member & Business Consultant


SAB member & Medical Consultant

Scientific Advisors

Research Collaborators

Screen Shot 2021-04-12 at 3.13.36 PM.png

Professor of Chemistry & Biochemistry at University of Southern Mississippi


Prof. of cancer biology at Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center

Screen Shot 2021-04-12 at 3.13.22 PM.png

Professor of Oncology at Rosewell Park Comprehensive Cancer Center, Editorial board member of J Exp Clin Can Res, Am J Transl Res, and Int J Mol Sci.



Cedars-Sinai Medical Center


University of Southern California

Screen Shot 2021-05-10 at 9.25.41 PM.png

Roswell Park Comprehensive Cancer Center


University of California Irvine


California Institute of Technology


University of Southern Mississippi

Scientific Advisors


Provost Professor in the Department of Biomedical Engineering and the Department of Biological Science at the University of Southern California

Screen Shot 2021-05-10 at 9.12.26 PM.png

Adjunct Professor at Case Western Reserve University and California Institute of Technology,  Emeritus President at Taipei Medical University in Taiwan

Screen Shot 2021-03-16 at 11.36.16

Professor Emeritus in the Department of Ophthalmology at UCSF, Director of the Retina Service at the San Francisco VAMC

Research Collaborators
Scientific Approach

Single Protein Encapsulation 

A novel drug delivery platform


SPE Technology Advantages: 

 (I), No nanoparticles (NP). After encapsulating small-molecule drugs, the proteins do not change either their sizes or their monomeric states, resulting in non-existence of the nanoparticles. Therefore, there is a very low probability of activating immune responses in humans, which is in stark contrast to many synthetic polymer- and NP-based systems.

(II), No chemical modifications to either drug or protein molecules.  The physical interactions between drug and protein molecules warrant the integrity of drug and protein molecules, which eliminates the cleavable linkers and completely retains the full functions of both drug and protein molecules. 


(III), Robustness in the manufacturing processes.   Because of no nanoparticles and no chemical modifications, the productions of SPE-DRUGs in large quantity under cGMP have been extremely simplified, requiring no separations and no purifications.  Therefore, the quality of the final drug products is consistently excellent.


Protein Molecules:  Human serum albumin (HSA) & other albumins, monoclonal antibodies, polyclonal antibodies 

Drug Molecules:  Anticancer drugs, antiviral drugs, antifungal drugs, etc.



Drug Molecules: 

The SPE technology is very versatile and can be applied to a broad spectrum of therapeutics. The drug molecules include, not limited to, (A) Anticancer drugs, such as doxorubicin, epirubicin, docetaxel, topotecan, camptothecin, daunorubicin, mitoxantrone, idarubicin, vincristine, vinblastine, vinblastine, SN-38, MMAE, MMAF, exatecan, ixabepilone, eribulin, etc;  (B) Antiviral drugs, such as remdesivir, ivermectin, ritonavir, Lopinavir, Umifenovir, etc.   (C) Antibiotics and antifungal drugs, such as rifampicin, clofazimine , amphotericin B , etc.

Protein Molecules: 

Various proteins can be used for the encapsulations of various drug molecules. The proteins include, not limited to, (A) Albumins, such as human serum albumin (HSA), bovine serum albumin (BSA), horse serum albumin, other mammal albumins; (B) Monoclonal antibodies, such as trastuzumab, sacituzumab, belantamab, enfortumab, polatuzumab, moxetumomab, inotuzumab, moxetumomab, gemtuzumab, brentuximab , etc.;  (C) Polyclonal antibodies, such as human Immunoglobulin G, etc. 



Screenshot 2023-09-22 at 8.38.31 PM.png
Screenshot 2024-03-01 at 6.58.27 PM.png
Screenshot 2024-03-01 at 6.58.07 PM.png

Latest News and Publication


1.  Sunstate Biosciences collaborates with Dr. Cui from Cedars-Sinai hospital to  to advance the development of SPEDOX-6 and SPE-SN38. The partnership is expected to accelerate the development of new treatment options for cancer patients and ultimately improve their quality of life.

2. FDA has granted orphan drug designation to SPEDOX-6 for the treatment of soft tissue sarcoma on 11/15/2022.

3.  Cedars-Sinai investigators test SPEDOX-6, showing it is safer for the heart than the current formulation. Their study published in the peer-reviewed journal Stem Cell Reports



Enclosing drugs inside a protein molecule shows potential as a method to safely deliver more cancer-fighting treatment directly to the tumor, according to a recent multi-institutional study. In tests performed in laboratory mice, the buffering method unleashed powerful tumor-killing drugs into cancer cells while leaving healthy tissues alone. If results from the study are duplicated in human trials, the protein-capsule delivery method potentially could be developed into a treatment that ferries more anticancer drugs to tumor sites and improves outcomes for patients with aggressive cancers. >>>>

Contact Us
Sitting on a Bench

Contact Us

Thanks for submitting!

bottom of page